Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …

Purpose Erlotinib prolongs survival in patients with advanced non–small-cell lung cancer
(NSCLC). We report the results of a randomized, phase II study of erlotinib alone or …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …

Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …